Literature DB >> 15743679

Potential oncogenic action of tenascin-C in tumorigenesis.

Gertraud Orend1.   

Abstract

The prominent expression of tenascin-C in the stroma of most solid tumors, first observed in the mid 1980s, implicates tenascin-C in tumorigenesis. This is also supported by in vitro experiments that demonstrate the capacity of tenascin-C to stimulate tumor growth by various mechanisms including promotion of proliferation, escaping immuno-surveillance and positively influencing angiogenesis. However, tumorigenesis in tenascin-C knock-out mice is not significantly different from that observed in control animals. Perhaps this is not unexpected if one considers that tenascin-C may act as an oncogene. The potential role of tenascin-C in tumorigenesis through its oncogenic action on cellular signaling will be discussed in this review, including how tenascin-C mediated tumor cell detachment might affect genome stability.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15743679     DOI: 10.1016/j.biocel.2004.12.002

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  42 in total

Review 1.  Molecular imaging with nucleic acid aptamers.

Authors:  H Hong; S Goel; Y Zhang; W Cai
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  Identification of glycoproteins from mouse skin tumors and plasma.

Authors:  Yuan Tian; Karen S Kelly-Spratt; Christopher J Kemp; Hui Zhang
Journal:  Clin Proteomics       Date:  2008-12-01       Impact factor: 3.988

Review 3.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

4.  Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease.

Authors:  Kim Midwood; Sandra Sacre; Anna M Piccinini; Julia Inglis; Annette Trebaul; Emma Chan; Stefan Drexler; Nidhi Sofat; Masahide Kashiwagi; Gertraud Orend; Fionula Brennan; Brian Foxwell
Journal:  Nat Med       Date:  2009-06-28       Impact factor: 53.440

5.  Tenascin-C-derived peptide TNIIIA2 highly enhances cell survival and platelet-derived growth factor (PDGF)-dependent cell proliferation through potentiated and sustained activation of integrin α5β1.

Authors:  Rika Tanaka; Yutaka Seki; Yohei Saito; Sadahiro Kamiya; Motomichi Fujita; Hiroaki Okutsu; Takuya Iyoda; Tatsuya Takai; Toshiyuki Owaki; Hirofumi Yajima; Junichi Taira; Ryo Hayashi; Hiroaki Kodama; Takuya Matsunaga; Fumio Fukai
Journal:  J Biol Chem       Date:  2014-05-07       Impact factor: 5.157

6.  Tenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesis in vitro.

Authors:  Enrico Martina; Martin Degen; Curzio Rüegg; Adrian Merlo; Maddalena M Lino; Ruth Chiquet-Ehrismann; Florence Brellier
Journal:  FASEB J       Date:  2009-11-02       Impact factor: 5.191

7.  Suppression of injury-induced epithelial-mesenchymal transition in a mouse lens epithelium lacking tenascin-C.

Authors:  Sai-ichi Tanaka; Takayoshi Sumioka; Norihito Fujita; Ai Kitano; Yuka Okada; Osamu Yamanaka; Kathleen C Flanders; Masayasu Miyajima; Shizuya Saika
Journal:  Mol Vis       Date:  2010-07-01       Impact factor: 2.367

Review 8.  Breast tumor microenvironment: proteomics highlights the treatments targeting secretome.

Authors:  Shui-Tein Chen; Tai-Long Pan; Hsueh-Fen Juan; Tai-Yuan Chen; Yih-Shyan Lin; Chun-Ming Huang
Journal:  J Proteome Res       Date:  2008-02-22       Impact factor: 4.466

9.  The role of tenascin-C in tissue injury and tumorigenesis.

Authors:  Kim S Midwood; Gertraud Orend
Journal:  J Cell Commun Signal       Date:  2009-10-17       Impact factor: 5.782

10.  Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics.

Authors:  John S Vorhies; John J Nemunaitis
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.